Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Visudyne verteporfin: Phase III; approvable in U.S. and marketed in Switzerland

QLT and partner Ciba Vision Corp. (Atlanta, Ga.) said that 2-year data from 609 patients in two Phase III trials showed a sustained benefit with fewer

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE